Swiss pharma group Novartis has said it will expand its US manufacturing and research and development with a $23bn investment over five years, as drugmakers reconfigure their supply chains as part of preparations for potential US tariffs.
Novartis, which makes a wide range of medicines from cancer to cardiovascular drugs, said the investments will enable it to produce all of its key US drugs in the country. It will build seven new facilities and expand others.
Vas Narasimhan, chief executive of Novartis, said the investments reflected the “pro-innovation policy and regulatory environment in the US that supports our ability to find the next medical breakthroughs for patients”.
您已阅读31%（684字），剩余69%（1519字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。